Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Blueprint Medicines has raised $1.3B in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2022.
Blueprint Medicines's investors include RA Capital Management, Wellington Management, Sixth Street, Perceptive Advisors, Redmile Group.
Blueprint Medicines is headquartered in Cambridge, United States.
Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Blueprint Medicines is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Blueprint Medicines — Funding & Investors." VCBacked, June 30, 2022, https://www.vcbacked.co/company/blueprint-medicines. Accessed August 14, 2026.
VCBacked. (2022). Blueprint Medicines — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/blueprint-medicines
{{cite web |title=Blueprint Medicines — Funding & Investors |url=https://www.vcbacked.co/company/blueprint-medicines |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated